Last Updated: September 28, 2026

Journey Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for JOURNEY

JOURNEY has nine approved drugs.

There are thirty-one US patents protecting JOURNEY drugs.

Summary for Journey

US Patents:	31
Tradenames:	7
Ingredients:	4
NDAs:	9
Patent Litigation for Journey:	See patent lawsuits for Journey

Drugs and US Patents for Journey

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Journey	XIMINO	minocycline hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	201922-001	Jul 11, 2012		DISCN	No	No	7,541,347	⤷ Start Trial				⤷ Start Trial
Journey	XIMINO	minocycline hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	201922-003	Jul 11, 2012		DISCN	No	No	7,919,483	⤷ Start Trial				⤷ Start Trial
Journey	EURAX	crotamiton	LOTION;TOPICAL	009112-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No		⤷ Start Trial				⤷ Start Trial
Journey	ZILXI	minocycline hydrochloride	AEROSOL, FOAM;TOPICAL	213690-001	May 28, 2020		RX	Yes	Yes	10,213,512	⤷ Start Trial	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Journey

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Journey	XIMINO	minocycline hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	201922-001	Jul 11, 2012	5,908,838	⤷ Start Trial
Journey	XIMINO	minocycline hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	201922-003	Jul 11, 2012	8,268,804	⤷ Start Trial
Journey	EXELDERM	sulconazole nitrate	SOLUTION;TOPICAL	018738-001	Aug 30, 1985	4,055,652	⤷ Start Trial
Journey	XIMINO	minocycline hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	201922-005	Jul 11, 2012	7,790,705	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for Journey Drugs

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Israel	240684	⤷ Start Trial
Canada	2776474	⤷ Start Trial
South Korea	20190138676	⤷ Start Trial
China	105026369	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Journey Drugs

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3089735	C03089735/01	Switzerland	⤷ Start Trial	PRODUCT NAME: GLYCOPYRRONIUMBROMID, FORMOTEROLFUMARAT-DIHYDRAT UND BECLOMETASONDIPROPIONAT; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67223 06.05.2020
2435024	LUC00208	Luxembourg	⤷ Start Trial	PRODUCT NAME: COMBINAISON DE FORMOTEROL (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES), DE GLYCOPYRRONIUM (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES) ET DE BUDESONIDE (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/20/1468 20201210
2515855	CA 2018 00002	Denmark	⤷ Start Trial	PRODUCT NAME: A COMBINATION OF GLYCOPYRRONIUM BROMIDE, FORMOTEROL OR A SALT THEREOF, INCLUDING FORMETOROL FUMARATE DIHYDRATE AND BECLOMETASONE DIPROPIONATE; REG. NO/DATE: EU/1/17/1208 20170719
1267866	122014000025	Germany	⤷ Start Trial	PRODUCT NAME: GLYCOPYRRONIUM ODER EIN SALZ ODER DERIVAT HIERVON (KOMPONENTE 1) UND INDACATEROL ODER EIN DERIVAT HIERVON ODER EIN SALZ VON INDACATEROL ODER EINEM DERIVAT HIERVON (KOMPONENTE 2); REGISTRATION NO/DATE: EU/1/13/862 20130919
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Journey

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.